1. Results of a Phase II Study of Guadecitabine in Higher Risk MDS Patients Refractory to or Relapsing after Azacitidine Treatment. (April 2017) Authors: Sebert, M.; Bally, C.; Peterlin, P.; Beyne-Rauzy, O.; Legros, L.; Gourin, M.P.; Sanhes, L.; Wattel, E.; Gyan, E.; Park, S.; Stamatoullas, A.; Laribi, K.; Banos, A.; Jueliger, S.; Chevret, S.; Ades, L.; Fenaux, P. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗